Skip to Main content Skip to Navigation
Journal articles

Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension

Abstract : Pulmonary arterial hypertension (PAH) is a devastating life-threatening disorder characterized by elevated pulmonary vascular resistance leading to elevated pulmonary arterial pressures, right ventricular failure and ultimately death. Vascular endothelial cells mainly produce and secrete endothelin (ET-1) in vessels that lead to a potent and long-lasting vasoconstrictive effect in pulmonary arterial smooth muscle cells. Along with its strong vasoconstrictive action, ET-1 can promote smooth muscle cell proliferation. Thus, ET-1 blockers have attracted attention as an antihypertensive drug and the ET-1 signaling system has paved a new therapeutic avenue for the treatment of PAH. The present chapter outlines not only the current understanding of the pathogenic role played by ET-1 signaling systems in the pathogenesis of PH, but also on the clinical pharmacology of endothelin receptor antagonists (ERA) used in the treatment of PAH.
Complete list of metadata

https://www.hal.inserm.fr/inserm-03224640
Contributor : Christophe Guignabert <>
Submitted on : Tuesday, May 11, 2021 - 8:51:33 PM
Last modification on : Saturday, July 3, 2021 - 12:19:53 AM
Long-term archiving on: : Thursday, August 12, 2021 - 7:33:56 PM

File

Clinical pharmaco ETRA_Am J Ca...
Files produced by the author(s)

Identifiers

Citation

Marie-Camille Chaumais, Christophe Guignabert, Laurent Savale, Xavier Jaïs, Athénaïs Boucly, et al.. Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, Springer Verlag, 2015, 15 (1), pp.13-26. ⟨10.1007/s40256-014-0095-y⟩. ⟨inserm-03224640⟩

Share

Metrics

Record views

56

Files downloads

92